• Veracyte published an investor presentation highlighting ASCO data on Prosigna in the OPTIMA phase III trial for ER-positive, HER2-negative early breast cancer.
• In the per-protocol ROR ≤60 group, 5-year invasive breast cancer-free survival was 93.6% in the test-directed arm versus 94.8% in the control arm.
• Adjusted hazard ratio was 1.06 with a 90% CI of 0.80-1.40; non-inferiority met with p=0.003.
• Across the broader low-risk analysis shown, 5-year invasive breast cancer-free survival was 90.3% versus 91.8%; adjusted hazard ratio 1.03, 90% CI 0.85-1.25.
• Presentation also cited Decipher evidence in metastatic prostate cancer from ENZAMET, using DGC >0.85 to identify docetaxel benefit with ADT, enzalutamide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.